Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Strategic Projects - Group

McGill University

$109,000.00

Development of novel magnesium alloys with impoved biocorrosion and mechanical behavior for cardiovascular implants

FY 2012-13

Summary
Cardiovascular diseases are the leading cause of premature death in developed countries like Canada. Many such diseases are now treated by inserting medical devices (e.g. intracardiac occlusive devices, intra-vascular stents) implanted through percutaneous or minimally invasive approach. Most implants are of permanent materials (stainless steel, cobalt) that may cause long-term erosion, irritation, inflammation, perforation, infection and lack of growth. Also, the surgical extraction or reintervention in the presence of these devices is difficult or impossible. Bio-degradable implants (e.g. stents) would eliminate these problems correcting the underlying pathology and ''fading away'' once the problem is fixed. In this multidisciplinary research, we integrated expertise in materials engineering, electrochemistry, cell biology and cardio-vascular clinical science & practice to develop optimal magnesium (Mg) alloy (s) for intravascular implant fabrication. The optimal alloys will be developed in a step-wise fashion to attain bio-corrosion resistance, bio-compatibility and mechanical integrity (strength, ductility); they will be tested via state-of-the-art in-vitro & in-vivo (with experimental animal model) preclinical studies. These new Mg alloy implants (stents) are expected to be significantly more biocompatible and function-efficient than those currently available. This will minimize postimplantation complications & the need for re-intervention, improve the quality of a patient's life, & decrease health care costs. 2010 figures for Canada estimate the use of 45000 bare metal stents (BMS) at $550/BMS and 45000 drug eluting stents (DES) at $1300/DES. The development of the biodegradable Mg alloys will create new technology for Baylis Medical, the supporting company, and will allow them to branch into the area of implantable therapeutic devices. The knowledge created will have high impact on biomedical implants technology. The research will also provide an excellent platform for training of high quality personnel in the multidisciplinary fields of materials development, electrochemistry, bio-medical & cardiovascular science, so that they will be positioned to advance this industry in Canada.
Program
Strategic Projects - Group
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
430385-2012
Name nom
Pekguleryuz, Mihriban
Department département
Mining & Materials Engineering.
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
109000
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1569
Committee name en
Strategic Projects Selection Panel - Manufacturing
Committee name fr
Comité de sélection des projets stratégiques - Fabrication
Area of application code
602
Area of application group en
Construction, urban and rural planning
Area of application group fr
Construction, urbanisme et aménagement rural
Area of application en
Materials performance
Area of application fr
Performance des matériaux
Research subject code
2000
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Materials science and technology
Research subject fr
Science et technologie des matériaux
Partie
1
Nb partie
3
Application title
Development of novel magnesium alloys with impoved biocorrosion and mechanical behavior for cardiovascular implants
Keyword
NSERC
Application summary
Cardiovascular diseases are the leading cause of premature death in developed countries like Canada. Many such diseases are now treated by inserting medical devices (e.g. intracardiac occlusive devices, intra-vascular stents) implanted through percutaneous or minimally invasive approach. Most implants are of permanent materials (stainless steel, cobalt) that may cause long-term erosion, irritation, inflammation, perforation, infection and lack of growth. Also, the surgical extraction or reintervention in the presence of these devices is difficult or impossible. Bio-degradable implants (e.g. stents) would eliminate these problems correcting the underlying pathology and ''fading away'' once the problem is fixed. In this multidisciplinary research, we integrated expertise in materials engineering, electrochemistry, cell biology and cardio-vascular clinical science & practice to develop optimal magnesium (Mg) alloy (s) for intravascular implant fabrication. The optimal alloys will be developed in a step-wise fashion to attain bio-corrosion resistance, bio-compatibility and mechanical integrity (strength, ductility); they will be tested via state-of-the-art in-vitro & in-vivo (with experimental animal model) preclinical studies. These new Mg alloy implants (stents) are expected to be significantly more biocompatible and function-efficient than those currently available. This will minimize postimplantation complications & the need for re-intervention, improve the quality of a patient's life, & decrease health care costs. 2010 figures for Canada estimate the use of 45000 bare metal stents (BMS) at $550/BMS and 45000 drug eluting stents (DES) at $1300/DES. The development of the biodegradable Mg alloys will create new technology for Baylis Medical, the supporting company, and will allow them to branch into the area of implantable therapeutic devices. The knowledge created will have high impact on biomedical implants technology. The research will also provide an excellent platform for training of high quality personnel in the multidisciplinary fields of materials development, electrochemistry, bio-medical & cardiovascular science, so that they will be positioned to advance this industry in Canada.